Evidence map›Paper›PMID 42057833›Full record

ArticleFrontiers in oncology2026

A case report of BCR-ABL(+) acute myeloid leukemia and literature review.

Jianping Li, Wei Zheng, Xueyan Dong, Jingyi Wang, Kui Liu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jianping LiDepartment of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Wei ZhengDepartment of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Xueyan DongDepartment of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Jingyi WangDepartment of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Kui LiuDepartment of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BCR-ABL(+) acute myeloid leukemia (AML) is considered a rare AML subtype with a short median survival time and poor prognosis. Currently, there is no unified standard treatment regimen for this disease, which complicates clinical diagnosis, treatment and medication selection. Case reports on this AML subtype remain relatively scarce to date. In this study, we present a case of BCR-ABL(+) AML that was treated with a TKI in combination with chemotherapy to induce remission, followed by allogeneic hematopoietic stem cell transplantation (Allo-HSCT). We also review the relevant literature to shed light on treatment strategies for BCR-ABL(+) AML and provide strong support for Allo-HSCT as a therapeutic option for this subtype.

Indexed as

allogeneic hematopoietic stem cell transplantationBCR-ABL(+) acute myeloid leukemiaprognosistreatmenttyrosine kinase inhibitors

Identifiers

PMID42057833
PMCPMC13121295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.